Evolving Practice Patterns for Multiple Myeloma

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.

Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.

Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.

Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.

Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.

Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.

Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.

Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.

A review of data from key clinical trials, including CANDOR and IKEMA, for relapsed/refractory multiple myeloma.

Cristina Gasparetto, MD; Sagar Lonial, MD, FACP; Joseph Mikhael, MD; and Nina Shah, MD, discuss emerging agents available for the treatment of RRMM.

Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.

Nina Shah, MD, leads the discussion on the role of CAR T-cell therapy, including idecabtagene vicleucel, for the management of RRMM.

Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.